Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, and its wholly owned subsidiary, Adivir Inc., have signed a second Amending Agreement with Appili Therapeutics Inc. (TSX: APLI) (OTC: APLIF) regarding its previously announced acquisition agreement. A biopharmaceutical company developing treatments and vaccines for infectious diseases and medical countermeasures, Appili has raised C$100 million toward developing its therapeutics since its inception in 2015. According to the amending agreement, the outside date of the acquisition and the date of Appili’s special shareholder meeting has been changed to Sept. 30, 2024. In addition, the deadline for Aditxt to complete necessary financing was changed to Sept. 15, 2024, or such later date as the parties may agree in writing. Through the acquisition, Aditxt will acquire all issued and outstanding Class A common shares of Appili. “Completing the acquisition of Appili Therapeutics will be another milestone in advancing our mission of making promising innovations possible, together,” said Aditxt cofounder, chair and CEO Amro Albanna in the press release. “The strategic importance of Appili’s work in developing treatments and vaccines for infectious diseases and medical countermeasures could impact millions of people around the globe. We believe Appili’s team and their product portfolio can potentially address some of the most urgent public-health challenges, including antibiotic-resistant infections and bioterrorism threats.”
To view the full press release, visit https://ibn.fm/Ny7zI
About Aditxt Inc.
Aditxt is an innovation platform dedicated to discovering, developing and deploying promising innovations. Aditxt’s ecosystem of research institutions, industry partners and shareholders collaboratively drives its mission to “Make Promising Innovations Possible Together.” The innovation platform is the cornerstone of Aditxt’s strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder’s voice is heard and valued, and empowers collective progress. Aditxt has a diverse innovation portfolio, including Adimune(TM) Inc., which is leading the charge in developing a novel class of therapeutics for retraining the immune system to combat organ rejection, autoimmunity and allergies. Adivir(TM) Inc. focuses on enhancing national and population health and impacting public health globally. Pearsanta(TM) Inc. delivers rapid, personalized and high-quality lab testing accessible anytime, anywhere, led by its CLIA-certified and CAP-accredited clinical laboratory based in Richmond, Virginia.
For more information about the company, please visit www.Aditxt.com.
NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
